Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
2012 1
2013 1
2014 1
2016 1
2018 2
2019 4
2020 2
2021 2
2022 3
2023 1
2024 5
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
Veltkamp R, Korompoki E, Harvey KH, Harvey ER, Fießler C, Malzahn U, Rücker V, Montaner J, Caso V, Sibon I, Ringleb P, Halse O, Hügen K, Ullmann S, Schuhmann C, Todd GP, Haas K, Palà E, Debette S, Lachaize M, D'Aoust T, Enzinger C, Ropele S, Fandler-Höfler S, Haidegger M, Wang Y, Wafa HA, Cancelloni V, Mosconi MG, Lip GYH, Lane DA, Haefeli WE, Foerster KI, Wurmbach VS, Nielsen PB, Hajjar K, Müller P, Poli S, Purrucker J, Laible M, D'Anna L, Silva Y, de Torres Chacon R, Martínez-Sánchez P, Boulanger M, Norrving B, Paré G, Wachter R, Ntaios G, Wolfe CDA, Heuschmann PU; PRESTIGE-AF Consortium. Veltkamp R, et al. Lancet. 2025 Mar 15;405(10482):927-936. doi: 10.1016/S0140-6736(25)00333-2. Epub 2025 Feb 26. Lancet. 2025. PMID: 40023176 Free article. Clinical Trial.
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study.
Farkas B, Bessissow T, Limdi JK, Sethi-Arora K, Kagramanova A, Knyazev O, Bezzio C, Armuzzi A, Lukas M, Michalopoulos G, Chaskova E, Savarino EV, Castiglione F, Rispo A, Schäfer E, Saibeni S, Filip R, Attauabi M, Fousekis FS, Bacsur P, Resál T, Bálint A, Ivány E, Szepes Z, Bősze Z, Fábián A, Bor R, Farkas K, Lakatos PL, Molnár T. Farkas B, et al. Among authors: ivany e. J Clin Med. 2024 Dec 20;13(24):7804. doi: 10.3390/jcm13247804. J Clin Med. 2024. PMID: 39768726 Free PMC article.
Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases.
Bacsur P, Resál T, Sarlós P, Iliás Á, Dalma Sümegi L, Kata D, Dávid A, Farkas B, Ivány E, Bálint A, Bősze Z, Fábián A, Bor R, Szepes Z, Afif W, Bessissow T, Farkas K, Lakatos PL, Molnár T. Bacsur P, et al. Among authors: ivany e. Therap Adv Gastroenterol. 2024 Oct 16;17:17562848241290636. doi: 10.1177/17562848241290636. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39464507 Free PMC article.
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.
Bacsur P, Shaham D, Serclova Z, Resál T, Farkas B, Sarlós P, Miheller P, Maharshak N, Zemel M, Shitrit AB, Yellinek S, Bálint A, Fábián A, Bor R, Bősze Z, Ivány E, Szepes Z, Farkas K, Tóth I, Lázár G, Vlkova K, Tremerova A, Zuskova P, Ábrahám S, Molnár T. Bacsur P, et al. Among authors: ivany e. Aliment Pharmacol Ther. 2025 Jan;61(2):335-345. doi: 10.1111/apt.18359. Epub 2024 Oct 28. Aliment Pharmacol Ther. 2025. PMID: 39468719 Free PMC article.
31 results